The U.S. market's high prices create the large profit pool necessary to fund risky drug development. If the U.S. adopted price negotiation like other countries, the global incentive for pharmaceutical innovation would shrink, resulting in fewer new drugs being developed worldwide.

The argument against adopting lower foreign drug prices is framed as a national security imperative. Proponents argue that such price controls would slash U.S. R&D investment, allowing China to dominate the bio-pharma sector and potentially weaponize future drug supply chains in a crisis.

The administration is leveraging the U.S.'s market power to demand "most favored nation" pricing from pharmaceutical companies. This forces them to offer drugs at the lowest price available in any other developed nation, slashing costs for American consumers.

While MFN pricing is seen as a major threat, it could have an unexpected positive effect. It would force companies launching new drugs to establish a GDP-adjusted global price from the start, ending the current system where the U.S. effectively subsidizes lower prices elsewhere.

Major pharmaceutical companies are now willing to deploy the "nuclear option" of pulling planned R&D investments to express displeasure with national drug pricing policies. This tactic, seen in the UK, represents a direct and aggressive strategy to pressure governments into accepting higher prices for innovative medicines.

The Most Favored Nation (MFN) policy forces a difficult choice: launch early in Europe and risk a lower US reference price, or delay the European launch to protect US revenue, slowing patient access. This dilemma upends traditional global launch strategies, creating commercial, ethical, and operational problems for pharma companies.

Both in the US (with Medicare/Medicaid) and China, the areas of medicine that see the most government spending on drugs also attract the most R&D investment. China strategically uses this mechanism to direct innovation towards its public health priorities.

Policies that cap prices on oral medications (the "pill penalty") warp investment incentives. Venture capitalists may stop funding companies developing pills, meaning promising academic research for these therapies might never be commercialized for patients.

Despite promises of affordability, MFN's price reductions primarily lower costs for the US government. For the majority of patients on fixed copay plans, their out-of-pocket expenses for a drug will not decrease even if the government negotiates a lower price. Only patients on coinsurance plans would see a direct reduction.